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Background: The rise of antibiotic resistance among methicillin resistant Staphylococcus aureus (MRSA), have
caused concerns for the treatment of MRSA infections. Hence, search for an alternative therapy for these infections
is inevitable. Folk Indian medicine refers to the use of leaf and stem bark powder of Tabernaemontana alternifolia
(Roxb) in treatment of skin infections, but no scientific report establishes its antibacterial activity.
Methods: Direct aqueous extracts and sequential aqueous extracts of the stem bark of T. alternifolia (using
petroleum ether and ethyl acetate as other solvents) were prepared by soxhlet extraction. The antibiotic sensitivity
profiles of the clinical isolates were determined against 18 antibiotics using disc diffusion method. The isolates were
identified by 16S rRNA gene sequencing. The methicillin resistance among S. aureus (MRSA) was confirmed by PCR
amplification of mecA gene. The disc diffusion method was used to determine the antibacterial activity of the
extracts. The micro-dilution method was used to determine the minimum inhibitory concentration (MIC) of the
extract against the test organism. To further evaluate the therapeutic potential of the extract, cell cytotoxicity was
checked on Vero cells by MTT assay. Chemical profiling of the extract was done by HPTLC method.
Results: The aqueous extracts of T. alternifolia stem bark exhibited antibacterial activity against Gram-positive
microorganisms, particularly against clinical isolates of MRSA and vancomycin resistant S. aureus (VRSA). The
minimum inhibitory concentration (MIC) of extract against the isolates ranged from 600–800 μg/ml. The extract did
not exhibit cytotoxic activity against Vero cells even at the concentration of 4 mg/ml. The chemical profiling
revealed presence of alkaloids, flavonoids, coumarins, saponins and steroids. Petroleum ether and ethyl acetate
extracts did not exhibit antibacterial activity.
Conclusion: Our results offer a scientific basis for the traditional use of T. alternifolia in the treatment of skin
infections, showing that the plant extract has an enormous potential as a prospective alternative therapy against
MRSA skin infections. The present study lays the basis for future studies, to validate the possible use of T. alternifolia
as a candidate in the treatment of MRSA infections.
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Infectious diseases are one of the world’s leading causes of
premature deaths [1]. Antibiotics which are widely used
for the treatment of infectious diseases are under constant
threat due to the emergence of antibiotic resistant patho-
gens such as methicillin resistant Staphylococcus aureus
(MRSA), multidrug resistant Pseudomonas aeruginosa,
vancomycin resistant Enterococcus (VRE) and multidrug
resistant Mycobacterium tuberculosis [2-6]. Among these,
MRSA has emerged as agents causing increasing threat of
nosocomial infections, more people have died of MRSA
infection in US hospitals than of HIV/AIDS and tubercu-
losis combined during 2007–2008 [7,8]. Hence, search for
novel antimicrobial compounds or alternative therapy for
these infections is inevitable.
Plant based medicines are widely used and form an
integral part of primary health care in many developing
countries across the globe [9-12]. Recently plants have
been explored to obtain crude natural extracts for testing
and further refinement to develop effective antimicrobial
drugs. In India there are different systems of medicine
practiced like Ayurveda, Siddha, Unani, Amchi and local
health traditions, which utilize a large number of plants or
herbs for the treatment of human diseases [13].
Many plant species widely explored for antimicrobial
compounds fall into the family Apocynaceae. Within this
family, the genus Tabernaemontana is well documented
for its biological activities such as antioxidant [14],
anticancer [15-17], antifertility/contraceptive [18,19], anti-
pyretic and anti-inflammatory [17,20], anti-mycobacterial
[14], and antimicrobial agent [21-23].
T. alternifolia (Roxb), also known as Ervatamia heyneana
(Wall) or T. heyneana (Wall) is endemic to India and found
in Goa, Karnataka, Kerala, Maharashtra and Tamil Nadu
states [24]. Traditionally a therapeutic preparation made
from leaf and stem powder of T. alternifolia (Roxb) in
combination with stem bark of Ficus racemosa, Ficus
benghalensis, Madhuca longifolia and Strychnos nux-
vomica is used to treat skin infections [25]. The other
plants, except T. alternifolia, used in this preparation have
reported antibacterial activity, but despite the traditional
use of T. alternifolia in treatment of skin infections, no
scientific report has focused on establishment of the anti-
microbial activity of the plant against pathogen [26-29]. We
therefore, under took this study to evaluate the antimicro-
bial potential of the extracts of stem bark of T. alternifolia
against pathogens causing skin infections, especially MRSA
and VRSA.
Methods
Collection of plant material
Stem bark was collected in sterile plastic bags from
Tamhini Ghat, a part of Western Ghats (18°28′21″ N,
73°25′07″ E) near Pune, Maharashtra, India. The plantidentity was validated at the Department of Biodiversity,
Abasaheb Garware College, Pune.
Preparation of extracts
The aqueous extracts of stem bark were prepared as
follows: Direct aqueous extract (DAE): The stem bark was
dried at 55°C overnight. Twenty gram of dried stem bark
was subjected to hot extraction using soxhlet appar-
atus with 200 ml of distilled water as solvent for
6 hours at 100°C (boiling water).
Sequential aqueous extract (SAE): Twenty gram of
dried stem bark was subjected to hot extraction using
soxhlet apparatus first with 200 ml petroleum ether as a
solvent for 2 hours followed with ethyl acetate for
2 hours and finally with distilled water for 6 hours at
100°C.
The crude extracts were concentrated at 55°C in a
clean and sterile glass petri plate. Final solution of
100 mg/ml was prepared in sterile distilled water for
aqueous extracts and in dimethyl sulfoxide (DMSO) for
ethyl acetate and petroleum ether extracts. The extracts
were filter sterilized using Millipore 0.22 μm filter and
stored at 4°C.
Test organisms and antibiotic sensitivity determination
Clinical isolates from skin and soft tissue infections were
obtained from Deenanath Mangeshkar Hospital, Pune.
These clinical isolates were collected by the hospital as a
part of the standard practice and made available for the
study. The type strains of Bacillus subtilis (ATCC 6633),
Staphylococcus aureus (ATCC 6538P), S. epidermidis
(ATCC 12228), Escherichia coli (ATCC 8739), methicillin
resistant S. aureus (ATCC 43300) were obtained from
NCIM, National Chemical Laboratory, Pune.
Antibiotic sensitivity pattern of clinical isolates was
determined by standard disc diffusion method according
to the standards prescribed by Clinical and Laboratory
Standards Institute (CLSI) (former NCCLS) [30].
DNA extraction and PCR
The genomic DNA extraction was carried out from freshly
grown bacterial cultures using Qiagen blood and tissue
DNA extraction kit (Qiagen, Madison USA), following the
manufacturer’s instructions. The isolates were identified by
16S rRNA gene sequencing method as described earlier
[31]. PCR amplification of 16S rRNA gene was done using
primers 27F 5′-AGAGTTTGATCATGGCTCAG-3′ and
1488R 5′-CGGTTACCTTGTTACGACTTCACC-3′. PCR
amplification involved a GeneAmp PCR system 9700
(Applied Biosystems Inc. USA). The PCR for mecA gene
was carried out as described earlier [32]. The DNA
sequencing was done using BigDye 3.1 sequencing termin-
ator kit and ABI 3730xl DNA analyzer (Applied Biosystems
Inc. USA).
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Antibacterial activity of the extract was determined as per
CLSI guidelines (formerly NCCLS guidelines) [30]. Briefly,
Whatmann filter paper no. 1 discs were prepared (diameter
6 mm). Discs were impregnated with 20 μl of 100 mg/ml
extract per disc and dried at room temperature. Bacterial
suspensions were prepared by suspending overnight grown
culture in sterile normal saline. The turbidity of bacterial
suspensions was adjusted to 2x106 cfu/ml and 100 μl of
suspension was spread on Muller-Hinton agar plate
(HiMedia Laboratories, India). The discs impregnated
with extract were placed on plate. The plates were incu-
bated at 37°C for 24 hours and the zones of inhibition
were measured. Ciprofloxacin discs (5 μg/disc) (HiMedia
Laboratories, India) were used as a positive control for
growth inhibition.
Determination of minimum inhibitory concentration
Minimum inhibitory concentration (MIC) was determined
by the microdilution broth method [33]. The plant
extracts were serially diluted with Mueller–Hinton broth
(HiMedia laboratories, India) to obtain the desired con-
centrations of 0.1 to 2 mg/ml. Bacterial suspensions were
prepared in the similar manner as described in disc diffu-
sion assay. One hundred microliter of the suspension was
added to serially diluted extract. The inoculated test tubes
were incubated at 37°C under aerobic conditions. Cipro-
floxacin (HiMedia Laboratories, India) was used as a posi-
tive control for growth inhibition, in concentration
ranging from 0.05 μg/ml to 10 μg/ml. Turbidity was
checked after 24 hours of incubation. The lowest concen-
tration of the extract that produced no visible growth
when compared to the control (tube containing no
inoculum) was considered as MIC.
Stability of antibacterial activity
At a regular interval of three days, the antibacterial
activity of the extract was checked against MRSA (DMH4)
isolate by well diffusion method for a period of 2 months
[34]. Briefly, wells of diameter 8 mm were bored in the pre
seeded Mueller–Hinton agar plates using a cork borer and
100 μl of SAE (20 mg/ml) was added in the well. The
plates were incubated at 37°C and the zones of inhibition
were measured after 24 hours. The zone of inhibition after
every 3 days was compared with the zone of inhibition on
day 1 (first reading) to check the stability of the antibacter-
ial activity of the extract.
Cell cytotoxicity of the aqueous extracts
Cytotoxicity of extract on Vero cells was measured by
microculture tetrazolium (MTT) assay [35]. For the
assays, 96-well microplate was seeded with 100 μl medium
containing 10,000 Vero cells in suspension. After 24 hr
incubation and attachment, the cells were treated withdifferent dilutions of DAE as well as SAE. Various dilu-
tions of the extracts were prepared from the stock solution
(100 mg/ml), and incorporated in cell culture (final con-
centrations ranging from 1 to 4 mg/ml), in quadruplicate.
Cell viability was determined after 24 hour incubation, by
adding tetrazolium salt (Sigma Aldrich, USA) and reading
the absorbance at 570 nm with a ELISA plate reader
Spectra MAX250 (Molecular Devices, USA). Tetrazolium
salts are cleaved to formazan dye by cellular enzymes (only
in the viable cells). The level of absorbance directly corre-
lates to the metabolically active cells.
Chemo-profiling of the extract
Chemical analysis of SAE was done by HPTLC (Camag,
Switzerland) Sequentially: Applicator – Linomat IV,
Scanner III; Plate was developed in a twin tray chamber.
Solvent system and spraying reagents were used as
described earlier [36].
Results
Identification and antibiotic sensitivity pattern of
pathogenic isolates
A total of 14 isolates were obtained from patients with skin
infections. Based on 16S rRNA gene sequence, the isolates
were identified as Pseudomonas aeruginosa (DMH 1),
Staphylococcus aureus (DMH 2 to DMH 8 and DMH 10 to
DMH 14), and Escherichia coli (DMH 9). The 16S rRNA
gene sequences of isolates are deposited at GenBank under
accession numbers HM559231 to HM559244. The drug
sensitivity pattern, represented in Table 1 revealed that all
the isolates were resistant to at least 4 different antibiotics,
showing that all isolates are multi-drug resistant. Eleven
out of twelve S. aureus strains were methicillin resistant
(MRSA). The presence of mecA gene in the isolates, as
demonstrated by PCR and sequencing, confirmed the
methicillin resistant nature of the isolates which was earlier
observed by disc diffusion assay. The mecA gene is the
structural gene present in MRSA for penicillin binding
protein 2a, which confers resistance to most of the βeta-
lactam antibiotics [32]. Four of the MRSA isolates were also
resistant to vancomycin, Table 1, thus making them VRSA.
Antibacterial activity and MIC of the aqueous extract
against bacterial pathogen
Both the hot aqueous extracts (DAE and SAE) exhibited
antibacterial activity against Gram positive organisms
such as B. subtilis, S. epidermidis, S. aureus and MRSA
but did not exhibit any antibacterial activity against
Gram negative organisms like E. coli and P. aeruginosa,
represented in Table 2. This observation is in accordance
with the antimicrobial activity obtained for other plant
species from the same genus, for eg., methanolic extracts
of T. chippi stem bark has reported antimicrobial activity
against Gram positive organisms and very weak activity
Table 1 Antibiotic sensitivity patterns of the test organisms
Antibiotics Isolates
DMH1 DMH2 DMH3 DMH4 DMH5 DMH6 DMH7 DMH8 DMH9 DMH10 DMH11 DMH12 DMH13 DMH14
Ampicillin R S R R R R R R R R R R R R
Cefuroxime R R R R R S R R R S R R R R
Cephadroxil R R R R R R R R R S S S S S
Augmentin R S R R R R R R R R R R R R
Penicillin R S R R R R R R R R R R R R
Azithromycin S R S R R S S S S S S R R S
Erythromycin R R S R R S S S R S S R IR S
Cefoperazone S S IR R S S IR S IR IR IR R S S
Clarithromycin R R S R R S S S R S S R IR S
Ciprofloxacin S S R R IR S S S R S IR R R R
Gatifloxacin S S S S S S S S R S S S S S
Aztreonam R R R R R R R R R R R R R R
Vancomycin R S R S S S S S R R S R S R
Doxycycline
Hydrochloride
R S S S S S S S R S S S S S
Norfloxacin S S IR IR IR S S S R S IR IR R R
Ofloxacin S S S S S S S S R S S S S S
Sparfloxacin S R S S S S S S R S S S S S
Methicillin R S R R R R R R R R R R R R
Legend: S sensitive, IR intermediate resistant, R resistant.
DMH 1: Pseudomonas aeruginosa, DMH 2 to DMH 8: Staphylococcus aureus, DMH 9: Escherichia coli, DMH 10 to DMH 14: Staphylococcus aureus.
Table 2 Zones of inhibition and MIC values for T. alternifolia stem bark aqueous extracts against the test organisms
Isolate
Zone of inhibition (mm) Minimum inhibitory concentration (μg/ml)
DAE SAE Ciprofloxacin (5 μg/disc) DAE SAE Ciprofloxacin
DMH 2 16 17 27 600 600 0.25
DMH 3 16 16 11 700 650 2
DMH 4 14 14 13 800 800 2
DMH 5 18 19 15 600 600 1.5
DMH 6 13 14 22 800 800 0.25
DMH 7 15 15 21 700 650 0.25
DMH 8 14 14 24 800 800 0.125
DMH 10 15 15 20 700 650 0.25
DMH 11 16 16 16 700 700 1.4
DMH 12 17 17 13 600 600 2.5
DMH 13 16 16 12 700 700 3
DMH 14 14 14 11 800 800 2
ATCC 6633 16 17 25 600 600 0.05
ATCC6538P 17 16 22 600 600 0.15
ATCC12228 17 16 24 600 600 0.1
ATCC 43300 17 17 22 600 600 0.15
Legend: All DMH isolates are Staphylococcus aureus among which DMH 3,10,12,14 are VRSA and all others except DMH2 are MRSA. ATCC 6633: Bacillus subtilis,
ATCC 6538P: Staphylococcus aureus, ATCC 12228: Staphylococcus epidermidis, ATCC 43300: MRSA.
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Figure 1 Consistent antimicrobial activity of SAE (sequential aqueous extract) against DMH 4 (MRSA). The X axis represents the number
of days after preparation of extract and Y axis represents the zone of inhibition (in mm) by well diffusion method.
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and T. stapfiana (Britten) have antimicrobial activity against
S. aureus [22,23].
The values for minimum inhibitory concentrations
(MIC) for DAE and SAE against the test organisms are
represented in Table 2. The MIC of extracts against MRSA
isolates fall in the range of 600–800 μg/ml as determined
by broth dilution method. The antibacterial activity of the
extract was stable even after 2 months as suggested by
consistent zone of inhibition by well diffusion method
(Figure 1). Petroleum ether and ethyl acetate extracts did
not exhibit any antibacterial activity. The MIC for cipro-
floxacin against MRSA isolates ranged from 0.125 μg/ml
to 3 μg/ml (Table 2).
Cell cytotoxicity of the aqueous extracts
The extracts did not exhibit any significant cytotoxicity
against Vero cell line at concentration ranging from 2 toFigure 2 Effect of DAE and SAE on Vero cell viability. The effect of DA4 mg/ml after 24 hrs of incubation. The SAE exhibited
less effect as compared to DAE (Figure 2). Three inde-
pendent experiments were carried out and statistical
significance was evaluated by Turkey test which is a
single-step multiple comparison statistical test.
Chemo-profiling of aqueous extract
HPTLC revealed presence of alkaloids, flavonoids, couma-
rins, saponins and steroids in the extract, however amides
and phenolics were absent. The number of spots and the
Rf values for each compound are represented in Table 3.
Discussion
Plant derived medicines have been a part of traditional
health-care in most parts of the world and the anti-
microbial property of plant-derived compounds is well-
documented [38]. For the first time here, we established
the antimicrobial activity of crude aqueous extract ofE and SAE on cell viability were significantly different at p < 0.05 level.
Table 3 Chemo profile of sequential aqueous extract of T. alternifolia stem bark performed by HPTLC method
Compound Number of spots observed Rf values
Alkaloids 2 0.77, 0.87
Flavanoids 11 0.03. 0.07, 0.35, 0.43, 0.5, 0.55, 0.6, 0.64, 0.68, 0.75, 0.8
Saponins 18 0.11, 0.17, 0.23, 0.25, 0.27, 0.34, 0.41, 0.45, 0.51, 0.53, 0.58, 0.63, 0.68, 0.84, 0.74, 0.56, 0.78, 0.84
Steroids 7 0.02, 0.04, 0.06, 0.15, 0.58, 0.78, 0.84
Coumarins 5 0.04, 0.07, 0.16, 0.57, 0.64
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by Duraipandiyan et al. in 2006, showed that the methanol
and hexane extract of stem bark of T. alternifolia did not
exhibit any antibacterial activity [25]. These observations
related to activity may be attributed to the fact that different
compounds from the plant material get extracted in
solvents of different polarities. Moreover, the fact that the
antimicrobial activity of both the SAE and DAE was similar
(as indicated by the MIC values) demonstrates that the
active principle in the plant stem bark was not extracted in
less polar solvents like hexane, ether, methanol, ethyl acet-
ate but got extracted in distilled water. During the
extraction process the active principle within the extract
survived boiling at 100°C for 6 hours suggesting that it is
heat stable. Such a heat stable active principle has been
previously reported from other plants [39,40].
Several studies have focused on establishment of anti-
bacterial activity of the plant extracts but have not
focused on showing the time dependent stability of its
activity [22,23,39]. Here we report that the activity of the
extract is stable over a period of 2 months after extrac-
tion. This indicates that the active principle present in
the aqueous extract of T. alternifolia stem bark has a
long shelf life in crude preparation. For a crude extract
to be used for topical applications it is mandatory that
the extract does not exhibit any cytotoxic activity.
Although anticancer alkaloid camptothecin has been
isolated from T. alternifolia; aqueous extracts in this
study did not show presence of camptothecin (data not
shown) [16]. The aqueous extracts did not exhibit any
significant cytotoxic effect against Vero cell line (Figure 2);
this is consistent with the absence of camptothecin in the
extracts. On exposure to SAE, the viable cell counts of
Vero cells were observed to be higher as compared to con-
trol, suggesting that SAE may have a probable positive ef-
fect on cell proliferation. The toxic compound/s present
in the stem bark were probably extracted in less polar sol-
vents during sequential extraction, thus, explaining the
observed positive effect on cell proliferation only on SAE
treatment.
The antimicrobial activity of the crude extract may be
attributed to a specific compound or a combination of
compounds. The knowledge about the chemical profile
of the extract helps in explaining the observed activity
and designing experiments for activity fractionation forisolation of the active principle. Alkaloids, flavonoids,
coumarins, saponins and steroids are the compounds of
plant origin known to have antibacterial activity. These
compounds were detected in the SAE [40-44]. Hence fur-
ther objective is to identify a potential lead compound,
which can be developed into a candidate anti-infective
drug, in particular for treatment of infections by
multidrug resistant pathogens like MRSA and VRSA.
In the past few decades, MRSA have caused a
major problem with nosocomial infections throughout the
world [7]. In the developed countries, fluoroquinolones
(ciprofloxacin and ofloxacin) are recommended for serious
infections associated with Staphylococci [45] but vanco-
mycin still remains the drug of choice for most MRSA-
associated diseases [46]. In this study four MRSA isolates
were resistant to vancomycin, five MRSA isolates were
resistant and two were intermediately resistant to cipro-
floxacin respectively, further emphasizing the difficulties
in treatment of MRSA infections with antibiotics (Table 1).
Moreover, in the last 2 decades, the number of new anti-
microbial drugs that reached the marketplace has fallen to
less than half the previous level [47]. Hence, more efforts
should be directed towards the screening for new anti-
microbial agents. The anti-MRSA activity exhibited by T.
alternifolia stem bark extracts seems a promising step
towards research for finding a new therapeutic agent
against MRSA. However, extensive research needs to be
carried out on this aspect of T. alternifolia.Conclusion
The aqueous extract of T. alternifolia has antibacterial
activity against MRSA and VRSA but does not retain
any cytotoxicity, which further validates the use of the
plant in traditional medicine. The present study lays the
basis for future research, to validate the possible use of
T. alternifolia as a candidate in the treatment of MRSA
infections.
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